Publications by authors named "Ilona G Reischl"
Article Synopsis
- Growing interest in extracellular vesicles (EVs), such as exosomes and microvesicles, highlights the need for standardization in their development as therapeutic tools, especially in stem cell therapy.
- A workshop was held by key organizations to address the challenges and opportunities in developing EV-based treatments, focusing on both preclinical and clinical stages.
- The review suggests specific action items that, if implemented, could improve the establishment of effective practices for EV therapies.
Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery.
View Article and Find Full Text PDFChallenges with advanced therapy medicinal products and how to meet them.
Nat Rev Drug Discov
March 2010
Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products, are at the cutting edge of innovation and offer a major hope for various diseases for which there are limited or no therapeutic options. They have therefore been subject to considerable interest and debate. Following the European regulation on ATMPs, a consolidated regulatory framework for these innovative medicines has recently been established.
View Article and Find Full Text PDFArticle Synopsis
- PLC-gamma1 activation in T cells requires a protein complex including LAT, Gads, and SLP-76, especially after T cell receptor stimulation.
- The recruitment of PLC-gamma1 to lipid rafts, or GEMs, depends on SLP-76, particularly its Gads-binding domain, although SLP-76's N-terminal sites are not needed for this recruitment.
- SLP-76 also plays a crucial role in facilitating PLC-gamma1 phosphorylation at Tyr(783) through its interactions with other signaling proteins like Vav and ITK, highlighting its importance in T cell signaling.
Phospholipase Cgamma (PLCgamma) is a ubiquitous gatekeeper of calcium mobilization and diacylglycerol-mediated events induced by the activation of Ag and growth factor receptors. The activity of PLCgamma is regulated through its controlled membrane translocation and tyrosine (Y) phosphorylation. Four activation-induced tyrosine phosphorylation sites have been previously described (Y472, Y771, Y783, and Y1254), but their specific roles in Ag receptor-induced PLCgamma1 activation are not fully elucidated.
View Article and Find Full Text PDFBackground: Fc epsilon RI expressed on the surface of human epidermal Langerhans' cells facilitates uptake of IgE-associated allergens and plays a pivotal role in the pathogenesis of atopic dermatitis. Seminal results from studies investigating Langerhans' cell Fc epsilon RI in skin biopsy sections or epidermal cell suspensions demonstrate the highest receptor expression in lesional skin of patients with active atopic dermatitis.
Objective: We sought to investigate and localize Fc epsilon RI expression on Langerhans' cells within a minimally disturbed tissue environment in clinically uninvolved skin and to compare receptor expression between healthy donors and patients with atopic dermatitis or other allergic diseases.